ALLURION TECHNOLOGIES INC SEC Filings

Allurion Technologies, Inc. has filed a resale registration covering up to 5,988,024 shares of common stock that may be sold from time to time by existing investors. This total consists of 2,994,012 shares issued in a November 2025 private placement and 2,994,012 shares issuable upon exercise of accompanying November 2025 Private Placement Warrants. Allurion will not receive proceeds from investors’ resale of these shares, but could receive up to approximately $5.0 million if all of the warrants are exercised in cash at an exercise price of $1.67 per share. As of January 5, 2026, 12,279,181 shares of common stock were outstanding. The company highlights that large, ongoing resales under this prospectus could put pressure on its stock price. Allurion develops a weight-loss platform built around its swallowable, procedure-free intragastric balloon and a digital Virtual Care Suite.

Allurion Technologies, Inc. has filed a prospectus supplement updating its Form S-1 registration statement covering up to 65,211,325 shares of common stock. The supplement incorporates a recent current report that details the results of the company’s 2025 annual meeting of stockholders held on December 18, 2025, where seven proposals were presented for a vote. The company notes there were sufficient votes to approve Proposals 3 through 7, so a contingent proposal to adjourn the meeting for additional solicitation was not needed. Allurion’s common stock trades on the NYSE under the symbol ALUR, which last closed at $1.47 per share on December 19, 2025, while its public warrants closed at $0.02 per warrant.

Allurion Technologies, Inc. has a prospectus supplement covering up to 56,548,268 shares of common stock, updating its existing S-1/A prospectus with information from a recent Form 8-K. The update attaches the report on the company’s 2025 Annual Meeting of Stockholders held on December 18, 2025, where seven proposals were considered and approved without needing an adjournment. Stockholders elected directors including Omar Ishrak, M.D., Douglas Hudson, and R. Jason Richey, with several other proposals receiving strong support based on the reported vote totals.

The company’s common stock trades on the NYSE under the symbol ALUR, and its public warrants trade under ALUR.WS. On December 19, 2025, the common stock last traded at $1.47 per share and the public warrants at $0.02 per warrant. Allurion is classified as an emerging growth company, which allows it to follow reduced public reporting requirements, and it reminds investors to review the risk factors in the base prospectus before investing.

Allurion Technologies, Inc. reported the results of its 2025 annual stockholder meeting held on December 18, 2025. Stockholders re-elected three directors — Omar Ishrak, M.D., Douglas Hudson, and R. Jason Richey — to serve until the 2028 annual meeting. They also ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Stockholders approved an amended and restated 2023 Stock Option and Incentive Plan that increases the shares authorized for issuance, updates the definition of Fully-Diluted Shares Outstanding, lowers the non-employee director compensation limit, and extends the plan term. They approved repricing certain outstanding stock options under that plan, and authorized issuing common shares upon conversion of Series B Preferred Stock and upon exercise of certain private placement warrants to comply with NYSE listing rules.

Stockholders also approved an amendment to the certificate of incorporation to allow a reverse stock split at a ratio between 1-for-1.5 and 1-for-20, with the exact ratio to be set by the Board. A contingent proposal to adjourn the meeting was not needed because all key proposals received sufficient support.

Allurion Technologies, Inc. director insider transactions show a mix of gifts and small open-market sales of common stock following a reverse stock split. The filing notes that on January 3, 2025, Allurion implemented a 1-for-25 reverse stock split, and all share amounts in this report are adjusted for that change. On October 3, 2025 and November 26, 2025, the director reported code "G" transactions, reflecting transfers of common stock between direct holdings and an indirect position held through the Davin Family Nominee Trust, at a reported price of $0.00 per share.

On December 3, 2025 and December 4, 2025, the trust reported code "S" sales of 1,606 common shares on each date, at prices of $1.48 and $1.5821 per share, respectively, reducing the indirect holdings reported for the trust to zero. The filing explains that the shares attributed to the trust are held by the Davin Family Nominee Trust, for which the reporting person and spouse serve as trustees, and that the reporting person disclaims beneficial ownership beyond any pecuniary interest.

ALUR has a shareholder planning to sell 3,212 shares of common stock under Rule 144. The proposed sale will be executed through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 12/02/2025 and an aggregate market value of 4,384.38. The filing notes that 9,262,586 shares of the issuer’s common stock are outstanding.

The shares to be sold were acquired in two transactions. One block of 2,608 shares was obtained on 08/01/2023 via a private placement from the issuer for cash or check. An additional 604 shares were acquired on 03/14/2025 as a stock award from the issuer as compensation. The person filing represents that they are not aware of any undisclosed material adverse information about the issuer’s operations.

Allurion Technologies, Inc. (ALUR) is asking stockholders to vote at its fully virtual 2025 annual meeting on December 18, 2025. Stockholders of record as of October 31, 2025, when 7,770,047 common shares were outstanding, may participate and vote.

Key items include electing three Class II directors to serve until 2028 and ratifying Deloitte & Touche LLP as independent auditor for 2025, after audit fees of $1,483,750 in 2024 and $2,617,825 in 2023. The Board also requests approval of an amended and restated 2023 equity incentive plan, which would significantly increase the share pool to up to 20% of fully diluted shares following a planned exchange transaction and add an automatic annual increase of up to 5% of fully diluted shares through 2035.

The proxy further seeks approval of a one-time option repricing for up to 110,990 deeply underwater options, resetting exercise prices to at least the market price on the approval date, subject to a one-year retention condition. Additional proposals cover preferred share issuance, private placement warrant share issuance, a potential reverse stock split, and the ability to adjourn the meeting if needed.

Allurion Technologies (ALUR) reports sharply weaker results for the quarter ended September 30, 2025. Revenue fell to $2.7 million from $5.4 million a year earlier, while the company swung from net income of $8.7 million to a net loss of $11.9 million, driven by lower sales and continued operating expenses. For the first nine months of 2025, revenue declined to $11.6 million from $26.5 million, with a net loss of $22.7 million versus net income of $2.4 million in the prior-year period.

Allurion ended the quarter with $6.1 million in cash and cash equivalents and total assets of $18.1 million, against total liabilities of $101.1 million, including a $49.9 million Revenue Interest Financing liability and $32.2 million of convertible notes payable. Stockholders’ deficit widened to $82.9 million, even after increasing common shares outstanding to 7,767,027 from 2,710,607 at December 31, 2024.

Allurion Technologies, Inc. filed a notice of late filing for its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, explaining that it needed extra time to prepare and review items that occurred after quarter end. That work is now complete, and the company expects to file the Form 10-Q on the date of this notice, within the five-day extension allowed.

Allurion expects to report total revenue of approximately $2.7 million for the three months ended September 30, 2025, compared with approximately $5.4 million a year earlier. Gross profit is expected to be about $1.3 million versus $3.1 million, with lower operating expenses: sales and marketing of about $3.1 million, research and development of about $2.0 million, and general and administrative of about $5.8 million. Loss from operations is expected to be approximately $9.6 million, improved from approximately $12.3 million in the prior-year quarter.